Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Deficiency in vitamin D may exacerbate autoimmune disease

Deficiency in vitamin D has been widely regarded as contributing to autoimmune disease, but a review appearing in Autoimmunity Reviews explains that low levels of vitamin D in patients with autoimmune disease may be a result rather than a cause of disease and that supplementing with vitamin D may actually exacerbate autoimmune disease.

9 Apr 2009

Oral contraceptives linked to greater risk of systemic lupus erythematosus

The ratio of women to men with the autoimmune disease systemic lupus erythematosus (SLE) is nine to one and the incidence increases after puberty.

8 Apr 2009

Gene linked to lupus might explain gender difference in disease risk

In an international human genetic study, researchers at UT Southwestern Medical Center have identified a gene linked to the autoimmune disease lupus, and its location on the X chromosome might help explain why females are 10 times more susceptible to the disease than males.

30 Mar 2009

Gene linked to lupus might explain why females are 10 times more susceptible to the disease

30 Mar 2009

Protein from tick saliva shows potential for myasthenia gravis treatment

Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Dendritic cells ensure immune tolerance

One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis. The only way to protect against these afflictions is to destroy all immune factors that turn against the body's own tissue - in other words: immune tolerance.

16 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

A vaccine for multiple sclerosis

Apitope Technology Ltd is a biopharmaceutical company that specialises in developing treatments for allergy and autoimmune diseases.

11 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Cultured stem cells and bioengineered skin used to successfully treat scleroderma

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines.

5 Mar 2009

New study using combination of bioengineered skin and stem cells shows promise in treatment of non-healing wounds

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

5 Mar 2009

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Mar 2009

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

Newly discovered protein points to new treatment for serious lung disease

The discovery by Uppsala University researchers of a previously unknown protein in the cells of the lower air ways brings new potential for early diagnosis of a serious lung disease.

2 Mar 2009

Epstein-Barr virus may be associated with progression of multiple sclerosis

Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.

2 Mar 2009

Compounds that trigger beta cell replication identified

Researchers at the Genomics Institute of the Novartis Research Foundation (GNF) have identified a set of compounds that can trigger the proliferation of insulin-producing cells in the pancreas, using sophisticated high-throughput screening techniques.

25 Feb 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009